Ensysce Biosciences ENSC
NASDAQ ENSC
$0.42 +0.02 (+3.96%)
At close: Sep 29, 2026 · 4:00 PM EDT

Ensysce Biosciences (ENSC) EBITDA Margin (2020 - 2021)

Updated

Ensysce Biosciences' EBITDA Margin was -122.71% in Q4 2021, up 139.78 percentage points from -262.50% a year earlier and up 1283.56 percentage points from the prior quarter.

Analysis

Ensysce Biosciences (ENSC) EBITDA Margin (2020 - 2021) Analysis & Trends

For FY2021, EBITDA Margin at Ensysce Biosciences came in at -562.71%, down 521.67 percentage points from FY2020.

  • In earlier years, EBITDA Margin was -41.03% in FY2020.
  • Quarterly EBITDA Margin has moved between -1406.27% (Q3 2021) and 7.62% (Q2 2020) over five years.
  • Per Business Quant data, ENSC's EBITDA Margin in the three quarters before Q4 2021 was -1406.27% (Q3 2021), -92.81% (Q2 2021) and -209.21% (Q1 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 Ensysce Biosciences 1.02 Mn -10.55 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -122.71%
Sep 30, 2021 -1,406.27%
Jun 30, 2021 -92.81%
Mar 31, 2021 -209.21%
Dec 31, 2020 -262.50%
Sep 30, 2020 -48.90%
Jun 30, 2020 7.62%
API Access

Ensysce Biosciences EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ENSC&period=max&api_key=YOUR_API_KEY